Dingji Bio Secures Tens of Millions of RMB in Series A Funding to Accelerate China Launch of World’s First Non-Invasive Continuous Respiratory Monitor

Mar 01, 2021 08:00 CST Updated 08:00

VCBeat learned at the earliest opportunity,Beijing Dingji Biotechnology Co., Ltd. (hereinafter referred to as “Dingji Biotech”) has recently completed a Series A financing round amounting to tens of millions of yuan.It is reported that the funds raised in this round will be primarily used for the construction, capacity expansion, and other production and operational activities of Dingji Biotech’s wholly-owned subsidiary in Henan Province. This initiative aims to accelerate the localized manufacturing of non-invasive dynamic respiratory monitors and their配套 disposable electrode sensors, thereby meeting both domestic and international market demands.

Dingji Bio focuses on the development of innovative medical devices, committed to becoming a global leader in respiratory monitoring and acute pain management through collaborative innovation and international mergers and acquisitions.This round of financing will accelerate Dingji Bio’s introduction of the world’s first non-invasive dynamic respiratory monitor into the Chinese clinical market.

Dr. Yang Weiping, Founder and Chairman of Dingji BiotechIntroduction: This non-invasive dynamic respiratory monitor is the world’s first product capable of providing precise and continuous monitoring of pulmonary ventilation for anesthetized patients without endotracheal intubation. It enables real-time, accurate monitoring of Minute Ventilation (MV), Tidal Volume (TV), and Respiratory Rate (RR) in such patients. Currently, there are no comparable competing products available in the Chinese market.

CoreSpiron Non-Invasive Dynamic Respiratory Monitor: Fast, Accurate, Comfortable, and Convenient—Superior to Conventional Monitoring

CoreSpiron Non-invasive Dynamic Respiratory Monitor enables non-invasive, dynamic, and continuous monitoring of minute ventilation (MV), the most direct indicator of respiratory function. It is as simple and easy to use as an electrocardiogram (ECG) and is suitable for preoperative assessment, intraoperative real-time monitoring, real-time monitoring during postoperative medication administration, post-anesthesia respiratory monitoring, neonatal and pediatric pulmonary function monitoring, and respiratory monitoring in critically ill patients.

图片鼎基生物.png

CoreSpiron Non-invasive Dynamic Respiratory Monitor

Compared with other conventional vital sign monitoring indicators traditionally used in clinical practice, the CoreSpiron non-invasive dynamic respiratory monitor offers the following advantages:

1. Rapidly Obtain Monitoring Values:The non-invasive dynamic respiratory monitor continuously monitors the patient's minute ventilation using patented non-invasive monitoring technology to obtain real-time monitoring data; the real-time respiratory monitoring data provides objective data support for clinical diagnostic decision-making.

2. Accurate Monitoring Data:Compared with the gold standard—spirometry—the non-invasive dynamic respiratory monitor achieved an accuracy of 93% in monitoring minute ventilation and 98% in monitoring respiratory rate.

3. High patient compliance:No endotracheal intubation is required, and the electrode sensor patches are clinically convenient to use.

Currently, there are no comparable competing products for this offering in the Chinese market. The product’s proprietary technological advantages and its substantial potential market demand were also decisive factors in Dingji Biology securing this round of financing. By establishing a production base in Henan Province, Dingji Biology has accelerated the localization of its manufacturing processes, while also enabling the export of disposable electrode sensor consumables compatible with its monitors to international markets.

Technical and Management Team: Global Perspective, Extensive Industry Experience

The core team members of Dingji Bio are all composite technical talents with many years of extensive experience in the industry. The company's R&D team is dedicated to the development of innovative medical devices, providing the talent support necessary for successfully introducing the globally unique non-invasive dynamic respiratory monitor to the Chinese market.

Dr. Yang Weiping, Founder and Chairman of Dingji BioWith over 30 years of industrial experience in China and the United States, Dr. Yang is a leading expert in the fields of medical devices and clinical diagnostics, as well as an adjunct professor at the Institute of Hepatology, Capital Medical University. Possessing a strong educational background in biomedicine and extensive R&D experience, Dr. Yang has successfully founded multiple medical device companies since returning to China more than a decade ago, making him a rare hybrid entrepreneur in the healthcare industry.

Prior to founding Dingji Biology, Dr. Yang served as Chief Technology Officer at Sichuan Maccura Biotechnology for eight years, where he established and led the company’s product research and development department. Additionally, Dr. Yang previously held the position of Senior Vice President and Chief Proteomics Scientist at CapitalBio Corporation in Beijing.

CompanyDr. Chunyuan Qiu, Chief ScientistHe is an international expert in the field of Anesthesiology and Perioperative Surgical Home (PSH), Chair of the Medical Performance Improvement Committee at Kaiser Permanente’s Baldwin Park Medical Center in California, Professor in the Department of Anesthesiology at the University of California, Irvine School of Medicine, and former President of the Association of American Medical Colleges.

Dingji Bio’s internationally oriented technical and management team, distinguished by its technological expertise, extensive experience, and global vision, provides the strong foundation for the company’s frequent overseas project collaborations and international mergers and acquisitions.

The product is about to receive certification, enabling rapid entry into the clinical markets of first- and second-tier cities in China.

According to Dr. Yang, Dingji Biotechnology’s non-invasive dynamic respiratory monitor is expected to obtain the Class II medical device registration certificate from the National Medical Products Administration by the end of the first quarter of 2021, and will be launched for sale in China in the second quarter of 2021.

Next, Dingji Biotech will rapidly penetrate the clinical markets in China’s first- and second-tier cities by strengthening its marketing channel infrastructure.